Publication:
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

Issued Date

2017-05-01

Resource Type

Article

ISSN

19326203

DOI

10.1371/journal.pone.0176428

Other identifier(s)

2-s2.0-85019165739

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

PLoS ONE. Vol.12, No.5 (2017)

Suggested Citation

Peter B. Gilbert, Jean Louis Excler, Georgia D. Tomaras, Lindsay N. Carpp, Barton F. Haynes, Hua Xin Liao, David C. Montefiori, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Gustavo H. Kijak, Sodsai Tovanabutra, Donald P. Francis, Carter Lee, Faruk Sinangil, Phillip W. Berman, Nakorn Premsri, Prayura Kunasol, Robert J. O'Connell, Nelson L. Michael, Merlin L. Robb, Rhoda Morrow, Lawrence Corey, Jerome H. Kim Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE. Vol.12, No.5 (2017). doi:10.1371/journal.pone.0176428 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/41461

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

Author(s)

Peter B. Gilbert
 Jean Louis Excler
 Georgia D. Tomaras
 Lindsay N. Carpp
 Barton F. Haynes
 Hua Xin Liao
 David C. Montefiori
 Supachai Rerks-Ngarm
 Punnee Pitisuttithum
 Sorachai Nitayaphan
 Jaranit Kaewkungwal
 Gustavo H. Kijak
 Sodsai Tovanabutra
 Donald P. Francis
 Carter Lee
 Faruk Sinangil
 Phillip W. Berman
 Nakorn Premsri
 Prayura Kunasol
 Robert J. O'Connell
 Nelson L. Michael
 Merlin L. Robb
 Rhoda Morrow
 Lawrence Corey
 Jerome H. Kim

Other Contributor(s)

Fred Hutchinson Cancer Research Center
 University of Washington, Seattle
 HJF
 Walter Reed Army Institute of Research
 Duke University School of Medicine
 Duke University Medical Center
 Thailand Ministry of Public Health
 Mahidol University
 Armed Forces Research Institute of Medical Sciences, Thailand
 Global Solutions for Infectious Diseases
 University of California, Santa Cruz
 International Vaccine Initiative

Abstract

© This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Background: In the HIV-1 vaccine trial RV144, ALVAC-HIV prime with an AIDSVAX® B/E boost reduced HIV-1 acquisition by 31% at 42 months post first vaccination. The bivalent AIDSVAX ® B/E vaccine contains two gp120 envelope glycoproteins, one from the subtype B HIV-1 MN isolate and one from the subtype CRF01-AE A244 isolate. Each envelope glycoprotein harbors a highly conserved 27-amino acid HSV-1 glycoprotein D (gD) tag sequence that shares 93% sequence identity with the HSV-2 gD sequence. We assessed whether vaccine-induced anti-gD antibodies protected females against HSV-2 acquisition in RV144. Methods: Of the women enrolled in RV144, 777 vaccine and 807 placebo recipients were eligible and randomly selected according to their pre-vaccination HSV-1 and HSV-2 serostatus for analysis. Immunoglobulin G (IgG) and IgA responses to gD were determined by a binding antibody multiplex assay and HSV-2 serostatus was determined by Western blot analysis. Ninety-three percent and 75% of the vaccine recipients had anti-gD IgG and IgA responses two weeks post last vaccination, respectively. There was no evidence of reduction in HSV-2 infection by vaccination compared to placebo recipients over 78 weeks of follow-up. The annual incidence of HSV-2 infection in individuals who were HSV-2 negative at baseline or HSV-1 positive and HSV-2 indeterminate at baseline were 4.38/100 personyears (py) and 3.28/100 py in the vaccine and placebo groups, respectively. Baseline HSV- 1 status did not affect subsequent HSV-2 acquisition. Specifically, the estimated odds ratio of HSV-2 infection by Week 78 for female placebo recipients who were baseline HSV-1 positive (n = 422) vs. negative (n = 1120) was 1.14 [95% confidence interval 0.66 to 1.94, p = 0.64)]. No evidence of reduction in the incidence of HSV-2 infection by vaccination was detected. Conclusions: AIDSVAX® B/E containing gD did not confer protection from HSV-2 acquisition in HSV-2 seronegative women, despite eliciting anti-gD serum antibodies.

Keyword(s)

Agricultural and Biological Sciences
 Biochemistry, Genetics and Molecular Biology

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/41461

Collections

Scopus 2016-2017